

Index of drug names

- Abilify. *See* aripiprazole
- Abilify Mycite. *See* aripiprazole, with sensor
- Adderall. *See* amphetamines
- alprazolam, 23, 25, 267, 270, 271, 274, 284
- amantadine, 68, 158
- Ambien. *See* zolpidem
- amisulpride, 169–70
- amitriptyline, 288–9, 301, 457
- amphetamines, 314, 409, 444–5
- aripiprazole, 43–4, 46–7, 103, 116, 117–20,
121–2, 149–50, 164–5, 261, 346–7, 348,
349, 353, 354, 355
LAI derivatives, 46, 50
with sensor, 50–1
- Aristada. *See* aripiprazole, LAI derivatives
- Ativan. *See* lorazepam
- atomoxetine, 323
- Austedo. *See* deutetrabenazine
- Auvelity. *See* dextromethorphan/bupropion
- Belsomra. *See* suvorexant
- Benedryl. *See* diphenhydramine
- benztropine, 332–3, 432
- brexpiprazole, 48, 120
- buprenorphine, 200, 204
- bupropion, 23, 25, 27, 201–3, 204, 205,
231–4, 409
- buspirone (BuSpar), 26, 272, 273
- cabergoline, 116
- carbamazepine, 68, 176, 253, 261, 262, 358,
429–30, 432, 439
- cariprazine, 9, 48, 120, 385, 391–2
- Catapres. *See* clonidine
- Celexa. *See* citalopram
- Chantix. *See* varenicline
- chlorpromazine, 253
- citalopram, 336, 346–7, 395, 478, 479
- clonazepam, 158, 184, 457
- clonidine, 197, 272, 278, 323, 372, 376
- clozapine (Clozaril), 91–107, 170–9, 327–41
- Cogentin. *See* benztropine
- Colace. *See* docusate
- Concerta. *See* methylphenidate
- Cymbalta. *See* duloxetine
- cyproheptadine, 158
- Dayvigo. *See* lemborexant
- Depakote. *See* divalproex
- Deplin. *See* L-methylfolate
- desipramine, 291, 301
- desvenlafaxine, 184, 187–8, 190, 320, 324, 372
- Desyrel. *See* trazodone
- deutetrabenazine, 153, 159
- dexmedetomidine sublingual, 278
- dextromethorphan/bupropion, 16
- dextromethorphan/quinidine sulfate, 8–9,
15–16
- Diflucan. *See* fluconazole
- diphenhydramine, 137
- divalproex, 68, 103, 220, 358, 426–8, 439
- docusate, 95, 96
- Dostinex. *See* cabergoline
- doxepin, 190, 443–4, 447–8, 461, 466
- duloxetine, 286, 288, 290, 395, 429, 453
- Effexor. *See* venlafaxine
- Elavil. *See* amitriptyline
- Equetro. *See* carbamazepine
- escitalopram, 270, 271, 407–8, 470, 473, 478,
479
- Eskalith. *See* lithium
- esketamine, 1–19, 26–7, 29, 32–3, 37
- eszopiclone, 463
- Fetzima. *See* levomilnacipran
- fluconazole, 45
- fluoxetine, 33, 202, 215, 218, 336, 478, 479,
480
- fluphenazine, 91
- fluvoxamine, 98, 99, 101, 103–4, 470, 471–2,
478, 479

Index of drug names

- gabapentin, 201, 286–7, 296, 305, 368, 376, 424, 429
 guanfacine, 278, 323, 445–6, 447
- haloperidol (Haldol), 111, 224, 382, 384
 hydrochlorothiazide, 320
 hydroxyzine, 73, 196, 332, 333
- Igalmi. *See* dexmedetomidine sublingual
 Inderal. *See* propranolol
 Ingrezza. *See* valbenazine
 Intermezzo. *See* zolpidem
 Intuniv. *See* guanfacine
 Invega. *See* paliperidone
 Invega Sustenna. *See* paliperidone, LAI derivatives
- Kapvay. *See* clonidine
 ketamine (Ketalar), 4–5, 11–13, 29, 32–3, 37
 Klonopin. *See* clonazepam
- lamotrigine (Lamictal), 103, 254, 261, 262, 268, 273, 424, 439
 lemborexant, 190, 193
 levomilnacipran, 9, 291
 Lexapro. *See* escitalopram
 lisdexamfetamine, 9, 136, 144, 321, 409
 lithium, 59, 60, 68, 91, 103, 218–25, 252–3, 261, 262, 358, 379–93, 425–6, 433, 439
 different formulations, 386–7, 390
 Lithobid (slow-release lithium), 387
 lorazepam, 58–9, 62–3, 67, 331, 351, 458
 Lunesta. *See* eszopiclone
 Luvox. *See* fluvoxamine
 Lyrics. *See* pregabalin
- melatonin, 74, 187–8, 189, 270
 memantine, 68
 L-methylfolate, 9
 methylphenidate, 149, 152, 321, 409, 444–5
 Microzide. *See* hydrochlorothiazide
 milnacipran, 291, 295, 296
 Minipress. *See* prazosin
 Mirapex. *See* pramipexole
 mirtazapine, 152, 203, 205, 235, 236, 241–3
 Mysoline. *See* primidone
- naloxone, 84
 naltrexone, 289, 294–5, 304
- Namenda. *See* memantine
 Narcan. *See* naloxone
 nefazodone, 34
 Neurontin. *See* gabapentin
 Norpramin. *See* desipramine
 nortriptyline, 288, 291, 301
 Nuedexta. *See* dextromethorphan/quinidine sulfate
- olanzapine, 69, 110, 135, 144, 174, 178, 215, 218, 261, 430
- paliperidone, 110, 112–16
 LAI derivatives, 50, 114, 116, 117–18
 Pamelor. *See* nortriptyline
 paroxetine (Paxil), 33, 84, 197, 336, 372, 470, 473, 474–6, 478, 479
 Periacetin. *See* cyproheptadine
 perphenazine, 178
 pramipexole, 116
 prazosin, 75, 197, 256, 279
 pregabalin, 286–7, 290, 296–7, 305
 primidone, 388
 Pristiq. *See* desvenlafaxine
 Prolixin. *See* fluphenazine
 propranolol, 278–9, 334, 386
 Prozac. *See* fluoxetine
- Qelbree. *See* viloxazine
 quetiapine, 120, 136, 137, 145, 196, 261, 262, 275, 316, 454
 quinidine, 16
- Remeron. *See* mirtazapine
 ReVia. *See* naltrexone
 Rexulti. *See* brexpiprazole
 risperidone (Risperdal), 43, 91, 122, 131, 136, 138, 144, 252
 Ritalin. *See* methylphenidate
- Savella. *See* milnacipran
 senna glycoside, 93
 Seroquel. *See* quetiapine
 sertraline, 23, 25, 33, 74, 77, 192, 197, 336, 453, 478, 479
 Serzone. *See* nefazodone
 Silenor. *See* doxepin
 Sinequan. *See* doxepin
 sodium oxybate, 302–3

Index of drug names

- Solian. *See* amisulpride
 Sonata. *See* zaleplon
 Spravato. *See* esketamine
 Stillnox. *See* zopiclone
 Strattera. *See* atomoxetine
 Subutex. *See* buprenorphine
 suvorexant, 190, 193, 466
 Symmetrel. *See* amantadine
- Tegretol. *See* carbamazepine
 Tenex. *See* guanfacine
 tetrabenazine, 158
 Thorazine. *See* chlorpromazine
 topiramate (Topamax), 68, 261
 tramadol, 288, 289, 302
 trazodone, 272, 316, 466
 Trilafon. *See* perphenazine
 Trintellix. *See* vortioxetine
- Ultram. *See* tramadol
- valbenazine, 153, 158
 valproic acid. *See* divalproex
 varenicline, 100, 102
- venlafaxine, 33, 228, 234, 246, 316–18, 324, 365, 367, 372
 vilazodone (Viibryd), 207, 475
 viloxazine, 323
 Vistaril. *See* hydroxyzine
 vitamin B6, 387
 Vivitrol. *See* naltrexone
 vortioxetine, 9
 Vraylar. *See* cariprazine
 Vyvanse. *See* lisdexamfetamine
- Wellbutrin XL. *See* bupropion
- Xanax. *See* alprazolam
 Xenazine. *See* tetrabenazine
 Xyrem. *See* sodium oxybate
- zaleplon, 463, 466
 Zoloft. *See* sertraline
 zolpidem, 23, 25, 67, 189, 458, 459, 461, 463, 466
 zopiclone, 463
 Zyprexa. *See* olanzapine

Index of case studies

- abnormal involuntary movement scale (AIMS),
151, 155–7, 336
- acetylcholine (ACh) receptors. *See*
anticholinergics
- ADHD. *See* attention deficit hyperactivity
disorder
- adherence to medication. *See* non-compliance
- adolescents
ADHD/psychosis/ASD, 133–46
depression/anxiety, 227–46
sleep hygiene, 237–8
suicidality and SSRIs, 234, 238–41
- aggression, 136
- agitation, 69–70, 135, 138, 275–9
- AIMS (abnormal involuntary movement scale),
151, 155–7, 336
- akathisia, 327–41
- alcohol use/abuse, 311, 315
naltrexone, 294–5
- alpha-1 receptor antagonists, 34, 75, 197, 256,
279
- alpha-2 receptor agonists,
ADHD, 445–6, 447
anxiety, 278
VMS, 372, 376
- alpha-2 receptor antagonists, 241–3
- alternative medicine, 357–8, 369, 472
- Altman Mania Rating Scale, 279
- amenorrhea, 115–16
- AMPA receptors, 14, 18–19, 32
- amygdala, 82, 259
- analgesia
in FM, 286–9, 290–1, 292–303, 305
other neuropathic pain, 201, 429, 457
- antenatal depression/anxiety, 345–60
- anticholinergics, 337–8
in the elderly, 432
for EPS, 137, 332–3
in myasthenia gravis, 256
- anticoagulants, 400
- anticonvulsants. *See individual drugs*
- antidepressants. *See also specific drug classes*
bipolar disorder, 269, 274, 429
breastfeeding, 359
depression and ADHD, 314, 316–18
DID/BPD/MDD, 75, 77
elderly patients, 448, 453–4, 460
insomnia, 447–8, 466
pain relief (in FM), 286, 288–9, 290, 296,
301, 305
pharmacogenomics, 319
SERT inhibition, 398–9, 400
sexual dysfunction, 199–214, 474–6
suicidality in adolescents, 234, 238–41
switching, 206, 212
- antihistamines
anticholinergic effect, 333
anxiolytic, 73, 196, 332
for insomnia, 73, 190, 461
- antihypertensives, 196, 320. *See also* alpha-1
receptor antagonists; alpha-2 receptor
agonists
- antipsychotics
agitation, 69–70, 135
akathisia, 327–41
baseline tests, 91, 349–50
bipolar disorder, 136, 382, 384–5, 424, 430
BPD, 261
catatonia, 62, 63, 64, 69–70
cross-titration, 117–18, 119, 120, 136, 138,
139
delirium/mania, 215, 218
DID, 83
dopamine system, 121–2, 144–6
dosage in children/adolescents, 136
dyskinesia, 149–50, 151, 154, 164–5
dystonia, 139, 142, 143
in the elderly, 432
hyperprolactinemia, 109–31
MDD, 349, 354
mechanisms of action, 121–2, 177, 354,
355, 391–2

Index of case studies

- antipsychotics (*cont.*)
 monitoring plasma levels, 112, 120, 129–30, 337
 myasthenia gravis, 253, 256
 non-compliance, 39–51
 pharmacokinetics, 46, 48–9, 51, 103–4, 329–30, 341
 in pregnancy, 346–7, 348, 353
 PTSD, 196
 schizophrenia, treatment-resistant, 87–107, 169–79
 smoking, 94, 95, 102, 174
 and stimulants, 133–46
- anxiety. *See also* social anxiety disorder
 comorbid MDD/PTSD, 21–37
 in pregnancy, 351
 social anxiety disorder, 22, 230, 233
- anxiolytics, 184, 332. *See also* benzodiazepines
 bipolar disorder, 272, 273, 274
 insomnia, 25, 73, 184, 332
 panic attacks, 284
 psychosis, 103
- anxious distress (in MDD), 269, 442, 443–4
- appetite loss, 234, 235, 246
- ASD. *See* autism spectrum disorder
- Attention-Deficit/Hyperactivity Disorder (ADHD)
 adult-onset with overlapping symptoms, 309–26
 AUD and BIF, 441–51
 comorbid psychosis/ASD, 133–46
 postpartum, and bulimia, 409–10
 symptoms, 323, 448
 treatment, 323, 444–5, 450
- atypical antipsychotics. *See* antipsychotics
- auditory hallucinations, 453–66
- autism spectrum disorder (ASD)
 aggression/agitation, 136, 138
 subsyndromal, 135
- autonomic dysfunction, 67, 222, 256
- Barnes akathisia rating scale (BARS), 339, 340
- Beers Criteria, 432
- Behcet's syndrome, 397
- benzodiazepine receptor agonists (BZRA), 351
 catatonia, 67
 depression, 23
 insomnia, 189, 458, 459, 461–2, 466
- benzodiazepines (BZ)
 akathisia, 331
 catatonia, 58–9, 62–3, 64–7
 comorbid MDD/anxiety/PTSD, 23, 25
 comorbid MDD/GAD, 267, 270, 271, 274
 in the elderly, 432
 and (es)ketamine, 9
 insomnia, 274, 351, 457, 458
 myasthenia gravis, 253
 panic attacks, 284
 in pregnancy, 351
 PTSD, 34, 195
 schizophrenia, 103
- beta blockers, 278–9
 akathisia, 334
 PTSD, 34
 tremors, 386
- BIF (borderline intellectual functioning), 451
- bipolar disorder (BP), 434
 antidepressants, 269, 274, 429
 antipsychotics, 136, 382, 384–5, 424, 430
 and BPD, 251, 254–5
 and catatonia, 60–1, 63
 conversion from MDD, 271, 280
 depression, 224–5, 279–80, 424, 434, 436
 elderly patient (BP1), 421–39
 long-term lithium use, 379–93
 mania, 136, 221, 436
 menopause, 375–6
 mixed features, 268
 and myasthenia gravis, 252–3
 screening tools, 275, 279–80
 treatment, 392, 435, 436, 439
- birth defects, 347–8, 358, 439
- black cohosh, 369
- bleeding, 395–401
- blood pressure, 27, 320
- blood tests
 antipsychotics, 93, 112, 120, 129–30, 337
 kidney failure, 423–4
 lithium, 221
- borderline intellectual functioning (BIF), 451
- borderline personality disorder (BPD)
 and ADHD, 315–16
 and BP2/MG, 249–62
 and depression, 313
 and DID, 74, 77, 80, 84
- BP. *See* bipolar disorder
- brain imaging
 BPD, 260
 DID, 82

- brain-derived neurotrophic factor (BDNF), 33
 Branford Hill Criteria, 224
 breastfeeding, 359, 408, 409, 439
 bruising, 395–401
 bulimia nervosa (BN), 407, 409–10
 Busch-Francis Catatonia Rating Scale, 55
 BZ. *See* benzodiazepines
 BZRA. *See* benzodiazepine receptor agonists
- caffeine, 104, 330
 calcium channel blockers
 pain, 201, 286–7, 290, 296, 305, 429
 VMS, 368, 376
 cannabis, 61, 311, 313, 315, 321, 322
 cardiac disorders, 69–70, 170, 272, 448
 catatonia, 53–70, 222–3
 CATIE trial, 178
 CBT (cognitive behavioral therapy), 245, 352
 CD (covert dyskinesia), 149–65
 cerebrovascular accident, 400
 childhood trauma
 BPD, 258
 MDD, 268
 chronic kidney disease (CDK), 423–4, 425–6,
 430, 431–2, 433, 439
 cigarettes. *See* smoking
 cognitive behavioral therapy (CBT), 245, 352
 cognitive decline, 464–5
 cold pressor time, 285
 complementary medicine, 357–8, 369, 472
 compliance. *See* non-compliance
 compulsivity, 412–13
 concentration, poor, 310, 323, 326
 confusion (lithium toxicity), 215–25
 constipation, 91, 93, 95, 96
 contraceptives, 176
 covert dyskinesia (CD), 149–65
 COVID-19
 clinical examinations, 155
 and clozapine, 330, 336
 school attendance, 232
 cytochrome P450 enzymes, 104
 antidepressants, 98, 319, 479
 antipsychotics, 46, 48, 49, 51, 103–4,
 129–30, 329–30, 341, 349
 caffeine, 104, 330
 CYP1A2, 98, 103–4, 105, 174, 175, 329–30,
 341
 CYP2C9, 175
 CYP2D6, 48, 49, 51, 175, 186, 190, 319,
 349
 CYP3A4, 46, 48, 51, 175, 176, 349
 smoking, 105, 174
 cytokines, 330
- DBT (dialectical behavioral therapy), 79,
 256–7
 deep brain stimulation (DBS), 416
 delirious mania, 223–4
 delirium
 antipsychotics, 69–70
 and catatonia, 55, 62, 63–4
 lithium toxicity, 215–25
 painkillers/UTI, 381–2, 388
 dementia, 464–5
 depression. *See also* major depressive disorder
 in adolescents, 227–46
 bipolar, 224–5, 279–80, 424, 434, 436
 and estrogen, 374
 sexual dysfunction, 199–214
 vegetative, 227–46
 dialectical behavioral therapy (DBT), 79, 256–7
 diarrhea, 427–8
 dissociation, in PTSD, 37
 dissociative identity disorder (DID), 71–85
 dopamine system
 ADHD, 449–50
 antipsychotics, 121–2, 144–6
 D₂ receptor agonists and hyperprolactinemia,
 116, 119–20
 D3 receptor antagonism, 391–2
 stimulants, 139, 144–6
 VMAT2 inhibitors and TD,
 dosing
 minimum therapeutic dose, 238
 subtherapeutic levels, 191–2, 274
 drug–drug interactions
 and CYP enzymes, 46, 48, 98, 175
 fluvoxamine+clozapine, 98, 99
 lithium+other, 220, 224
 oral contraceptives, 176
 drugs of abuse
 cannabis, 61, 311, 313, 315, 321, 322
 and catatonia, 55, 61, 63, 64
 DSM-5 criteria,
 delirium, 63–4
 DID, 82
 dynamic deconstructive psychotherapy, 257

Index of case studies

- dyskinesia
 AIMS scale, 151, 155–7, 336
 drug-induced, 149–65
 dystonia, 136–8, 140–6
- early life trauma
 BPD, 258
 MDD, 268
- eating disorders, 407, 409–10
 ECT. *See* electroconvulsive therapy
 Edinburgh Postnatal Depression Scale (EPDS),
 356–7
- elderly patients
 antidepressants, 448, 453–4, 460
 auditory hallucinations, 453–66
 BP1, 421–39
 hearing loss, 463–5
 insomnia, 460–1
 pharmacokinetics, 431–2, 433
- electrocardiography (EKG), 170, 448
 electroconvulsive therapy (ECT)
 catatonia, 67, 68
 clozapine failure, 103
 DID/BPD/MDD, 73, 75, 81
 TRS, 169, 179
- EMDR therapy (Eye Movement Desensitization
 and Reprocessing), 28, 187
- EPS. *See* extrapyramidal symptoms
 erectile dysfunction, 474–6
- estrogen
 in the brain, 370, 373
 and depression, 374
 HRT, 372
 oral contraceptives, 176
 phytoestrogens, 369
 receptors, 374
- extrapyramidal symptoms (EPS), 335–6
 akathisia, 327–41
 dyskinesia, 149–65
 dystonia, 136–8, 140–6
- FACES pain scale, 285
 fatigue, 149, 203, 212, 293
 febrile seizures, 232
 fibromyalgia (FM), 283–305
 5HT. *See* serotonin system
- GABA (gamma-aminobutyric acid)
 and serotonin, 243
- BZRAs, 67, 461
 BZs, 65, 66
 ketamine, 12
 sodium oxybate, 303
- gastrointestinal side effects
 bleeds, 400
 constipation, 91, 93, 95, 96
 diarrhea, 427–8
- generalized anxiety disorder (GAD), 22, 33, 201
 agitation, 275–9
 comorbid MDD, 265–80
 postpartum, 183, 185, 186
- genetics
 BPD, 258
 pharmacogenomics, 81, 103, 106, 175, 186,
 191, 319–20
- glutamate, 12–13, 32, 243, 449–50
 glutamate antagonists, 68
- hallucinations, musical, 453–66
 hearing loss, 463–5
 hemostasis, deranged, 395–401
 hepatic function, 432, *See also* cytochrome
 P450 enzymes
- herbal remedies, 369, 472
 hormone replacement therapy (HRT), 372
 hot flashes (vasomotor symptoms), 367, 369,
 370–1, 372, 373, 376
- hyperprolactinemia, 109–31
 hypersomnia, 232–3
 hypertension, 27, 320
 hypoactive sexual desire disorder (HSDD), 366,
 367–8, 371
- hypomania, 268–9
 hypothalamic-pituitary-adrenal (HPA) axis,
 258, 259
- imaging, brain
 BPD, 260
 DID, 82
- immunization, COVID-19, 330
 impulsivity, 412–13
 infants, breastfeeding, 359, 408, 409, 439
 insomnia
 auditory hallucinations, 456, 457, 458, 459
 effect on health, 462
 in the elderly, 460–1
 in postpartum PTSD, 187–90
 in pregnancy, 351

- sleep hygiene, 237–8
treatment, 189, 193, 272, 274, 351, 447–8, 461–2, 466
- intranasal esketamine spray, 5, 17
- intrusive thoughts, 405
- kidney function, 423–4, 425–6, 430, 431–2, 433, 439
- laboratory tests. *See* blood tests
- laryngospasm, 140–1
- liver function, 432, *See also* cytochrome P450 enzymes
- long acting injectable (LAI) antipsychotics, 50, 130
aripiprazole, 46
paliperidone, 114
- major depressive disorder (MDD)
adolescent, 227–46
and adult ADHD, 309–10, 313, 314, 326
agitation, 275–9
antipsychotics, 349, 354
anxious distress, 269, 442, 443–4
childhood trauma, 268
comorbid anxiety/PTSD, 21–37
comorbid GAD, 265–80
elderly patients, 453–4, 460
and fibromyalgia, 285
menopausal, 363–76
postpartum (with PTSD), 183–97
in pregnancy, 345–60
treatment resistant, 1–19, 29, 30
- malignant catatonia, 67, 222
- mania
BP1, 136, 221, 436
delirious, 223–4
lithium toxicity, 215–25
- MAOi (monoamine oxidase inhibitors), 30, 34
- mechanisms of action
antidepressants, 398–9, 478–9
aripiprazole, 121–2, 354, 355
BZs treat catatonia, 64–5
cariprazine, 391–2
clozapine, 177
gabapentinoids, 296
mirtazapine, 241–3
NMDA receptor antagonists, 11–13, 18–19, 32–3
orexin receptor antagonists, 193
sodium oxybate, 303
SPARIs, 207, 208, 209, 210, 211
venlafaxine/desvenlafaxine, 324
VMAT2 inhibitors for TD,
- menopause, 363–76
- mentalization-based therapy, 257
- methamphetamine, 55, 61, 63
- MG (myasthenia gravis), 252–3, 255–6, 262
- minimum therapeutic dose, 238
- monoamine oxidase inhibitors (MAOi), 30, 34
- Mood Disorders Questionnaire, 279
- mood stabilizers, 436, 439
bipolar depression, 224–5, 424
BPD/BD, 254, 260–1
and catatonia, 59, 60, 68
and kidney disease, 425–6, 433, 439
long-term lithium use, 379–93
and myasthenia gravis, 252–3, 262
in pregnancy, 358
psychosis, 103
teratogenicity, 358
toxicity, 215–25, 426–8, 429–30, 432
- movement disorders
akathisia, 327–41
dystonia, 136–8, 140–6
tardive dyskinesia, 149–65
tremors, 382, 385–9, 393, 431
- mTOR pathway, 14
- musical hallucinations (musical ear syndrome), 453–66
- myasthenia gravis (MG), 252–3, 255–6, 262
- nasal esketamine sprays, 5, 17
- NaSSA (norepinephrine antagonist / selective serotonin antagonists), 152, 203, 205, 235, 236, 241–3
- NDRI (norepinephrine–dopamine reuptake inhibitors)
ADHD and bulimia, 409
adolescent depression, 231–4
as alternative to SSRI, 201–3, 204, 205
- neurobiology
ADHD, 446–7, 448–50
BPD, 258–60
estrogen, 373, 374
fibromyalgia, 293
HPA axis, 258, 259
impulsivity and compulsivity, 412–13

Index of case studies

- neurobiology (*cont.*)
 OCD, 413–14, 415
 vasomotor symptoms, 372, 373
- neuropathic pain
 fibromyalgia, 283–305
 other, 201, 429, 457
- neurotransmitters. *See individual neurotransmitters*
- nicotine replacement therapy, 95, 171–2
 vaping, 173
- nightmares, 34, 75, 197, 279
- NMDA receptor antagonists,
 comorbid MDD/anxiety, 26–7, 32–3
 PTSD, 27, 31, 37
 treatment resistant MDD, 1–19, 29
- nocturnal enuresis, 96
- non-compliance
 antipsychotics, 39–51
 combating, 50–1, 77, 81, 111
 in DID/BPD, 71–85
 reasons for, 130, 370
- norepinephrine antagonist / selective serotonin
 antagonists (NaSSA), 152, 203, 205, 235,
 236, 241–3
- norepinephrine–dopamine reuptake inhibitors.
See NDRI
- norepinephrine system
 ADHD, 449–50
 agitation, 275–9
 ketamine, 13
 mirtazapine, 241–3
- NSAIDs (nonsteroidal anti-inflammatory
 drugs), 395
- obsessive compulsive disorder (OCD), 330,
 403–18
 with OCPD, 469–80
- obsessive compulsive personality disorder
 (OCPD), 471, 472, 476
- oculogyric crisis, 136–8, 140–1
- older patients. *See elderly patients*
- opioid use disorder (OUD), 200, 294–5
- opioids
 analgesic, 288, 289, 302, 305
 endogenous, 301
- oral contraceptives, 176
- oral dyskinesia, 150
- orexin receptor antagonists, 190, 193, 466
- oversleeping, 232–3
- pain
 fibromyalgia, 283–305
 measurement scales, 285, 286
 relief of neuropathic pain, 201, 286–9,
 290–1, 292–303, 305, 429, 457
- palliative psychiatry, 18
- panic disorder (PD), 266, 267–8, 271, 283, 284
- paranoia, new-onset, 384, 388
- perimenopause, 365–6
- perinatal mood and anxiety disorders (PMADs)
 depression/anxiety, 345–60
 OCD, 403–18
- pharmacogenomics, 81, 103, 106, 175, 186,
 191, 319–20
- pharmacokinetics. *See also cytochrome P450
 enzymes*
 antipsychotics, 46, 48–9, 51, 103–4,
 329–30, 341
 divalproex, 427
 elderly patients, 431–2, 433
 sleep medications, 466
 SSRIs, 479
- phytoestrogens, 369
- pituitary gland masses, 121
- platelets, 397, 399, 401
- post-traumatic stress disorder (PTSD), 22, 28,
 29–30, 406
 with DID/BPD/MDD, 78
 negative diagnosis, 267
 pharmacotherapy, 27, 31, 33–7, 195–7
 postpartum, 183–97
 psychotherapy, 30, 187, 196
- postpartum hemorrhage, 400
- postpartum OCD, 403–18
- postpartum psychosis, 406, 411
- postpartum PTSD and depression, 183–97
- prefrontal cortex (PFC), 32, 65, 244–5, 391,
 446–7, 448–50
- pregnancy
 depression/anxiety, 345–60
 drugs to avoid, 347–8, 358, 439
- Pregnancy and Lactation Labeling Rule (PLLR)
 (FDA), 347
- prolactin, and antipsychotics, 109–31
- psychodynamic psychotherapy, 235, 245
- psychological testing, 81, 84
- psychosis. *See also schizophrenia*
 comorbid ADHD/ASD, 133–46
 new-onset in BP1, 382–4, 388

- postpartum, 406, 411
- triggered by death of spouse, 215–16
- psychotherapy, 244–6
 - BPD, 255, 256–7
 - comorbid MDD/GAD, 270
 - depression/anxiety, 30, 235
 - OCD, 412
 - perinatal depression, 352, 357
 - PTSD, 30, 187, 196
- PTSD. *See* post-traumatic stress disorder
- QTc prolongation, 69–70, 170
- Rapid Mood Screener, 279
- red clover, 369
- relative infant dose (RID), 359, 408, 409
- renal function, 423–4, 425–6, 430, 431–2, 433, 439
- schizophrenia
 - clozapine-induced akathisia, 327–41
 - dosage in children/adolescents, 136
 - drug-induced hyperprolactinemia, 109–31
 - non-compliance, 39–51
 - treatment-resistant, 87–107, 167–80
- seizures, 232
- selective serotonin reuptake inhibitors. *See* SSRI
- serotonin discontinuation syndrome, 234, 479–80
- serotonin–norepinephrine reuptake inhibitors. *See* SNRI
- serotonin partial agonist / reuptake inhibitors (SPARI), 207, 208, 209, 210, 211, 475
- serotonin system
 - 5HT-1A partial agonism, 26, 207, 208, 209, 210, 211, 354, 356
 - 5HT-2A receptors, 142, 205
 - 5HT-3 receptors, 205, 243
 - platelet function, 399, 401
 - serotonergic drugs, 477–8
 - SERT inhibition, 13, 398–9, 400
- sexual dysfunction
 - antidepressants, 199–214, 474–6
 - and the menopause, 366, 367, 371
- side effects
 - anticholinergic drugs, 338, 432
 - antidepressants, 189, 199–214, 320, 395–401, 474–6
 - antipsychotics (in general), 69–70, 118, 142, 154, 335–6
 - aripiprazole, 149–50, 164–5
 - bruising/bleeding, 395–401
 - bupropion, 205
 - carbamazepine, 430, 439
 - clozapine, 91, 93, 96, 178
 - divalproex, 427–8, 439
 - ECT, 68
 - EPS, 136–8, 140–6, 149–65, 327–41
 - esketamine, 5
 - fluvoxamine, 471–2
 - glutamate antagonists, 68
 - of hyperprolactinemia, 121
 - hypertension, 27, 320
 - lamotrigine, 439
 - lithium, 222, 385–8, 389, 390, 393, 439
 - lorazepam, 67
 - mirtazapine, 203, 205
 - naltrexone, 294
 - olanzapine, 110
 - paliperidone, 112, 115
 - psychogenic origin, 191–2
 - sexual dysfunction, 199–214, 474–6
 - trazodone, 272
 - tremors, 382, 385–9, 393, 431
 - varenicline, 102
 - venlafaxine, 228, 234, 246
 - weight gain, 45, 110, 118, 203, 212
 - weight loss, 228, 234, 246
 - zolidem, 67, 461
- sigma 1 receptor, 13, 471–2, 478
- sleep disturbance
 - effect on health, 462
 - in the elderly, 460–1
 - hypersomnia, 232–3
 - insomnia. *See* insomnia
 - nightmares, 34, 75, 197, 279
 - sleep hygiene, 237–8
- smoking
 - cessation, 95, 100, 102, 171–2, 173
 - and clozapine, 94, 95, 96, 98, 100, 102, 171–2, 173
 - and CYP1A2, 105, 174
 - and olanzapine, 104, 174
- SNRI (serotonin–norepinephrine reuptake inhibitors)
 - adolescent depression, 234
 - bipolar disorder, 269, 429

Index of case studies

SNRI (*cont.*)

- bruising, 395–401
- depression and ADHD, 316–18, 320
- mechanisms of action, 324
- menopausal depression and VMS, 365, 367, 372, 376
- pain relief, 286, 288, 290–1, 295, 296, 305, 429, 453
- postpartum PTSD/MDD, 184, 186, 187–8, 190
- in pregnancy, 359
- PTSD, 33
- treatment-resistant MDD, 9
- weight loss, 228, 234, 246
- social anxiety disorder, 22, 230, 233
- soy products, 369
- SPARI (serotonin partial agonist / reuptake inhibitors), 207, 208, 209, 210, 211, 475
- SSRI (selective serotonin reuptake inhibitors)
 - bipolar disorder, 269
 - breastfeeding, 408
 - bruising, 395–401
 - in combination with clozapine, 98, 99, 101, 103–4, 336
 - DID/BPD/MDD, 74, 77, 84
 - discontinuation syndrome, 234, 479–80
 - MDD/anxiety/PTSD, 23, 25
 - MDD/GAD, 270, 271
 - OCD, 407–8, 417–18, 470, 473, 476, 477
 - pharmacodynamics, 478–9
 - pharmacokinetics, 479
 - in pregnancy, 346–7, 358–9, 360
 - PTSD, 33, 197
 - and sexual dysfunction, 213–14, 474–6
 - suicidality in adolescents, 234, 238–41
 - triggering mania, 215
 - vasomotor symptoms, 372
- steroids. *See* estrogen
- stimulant use disorder, 61, 63
- stimulants
 - ADHD, 139, 321, 444–5, 450
 - and antipsychotics, 133–46
 - breastfeeding, 409
 - dyskinesia, 152
 - MDD, 9, 149, 314
- stroke, hemorrhagic, 400

substance use disorders (SUD). *See also*

- cannabis
 - and ADHD, 445
 - naltrexone, 294–5
- suicidal ideation/attempts
 - BP, 251, 425, 431
 - depression, 310
 - drugs combating, 29, 174, 425
 - insomnia, 30
 - SSRIs in adolescents, 234, 238–41
- synaptogenesis, 13
- systems training for emotional predictability and problem-solving (STEPPS), 257
- tardive dyskinesia (TD), 149–65
- TCA (tricyclic antidepressants)
 - insomnia, 190, 447–8, 461, 466
 - MDD, 30, 443–4
 - pain relief, 288–9, 291, 300, 301, 305
 - PTSD, 34
- teratogenicity, 347–8, 358, 439
- Test of Memory Malingering, 84
- therapeutic drug monitoring
 - antipsychotics, 112, 120, 129–30, 337
 - lithium, 221
- tobacco use. *See* smoking
- transcranial magnetic stimulation (TMS), 68–9, 416
- transference-focused psychotherapy (TFP), 257
- treatment-resistant depression (TRD), 1–19, 29, 30
- treatment-resistant schizophrenia (TRS), 87–107, 167–80
- tremors, 382, 385–9, 393, 431
- tricyclic antidepressants. *See* TCA
- vaccination, COVID-19, 330
- valerian, 472
- vaping, 173
- vasomotor symptoms (VMS), 367, 369, 370–1, 372, 373, 376
- vegetative depression, 227–46
- VMAT2 inhibitors, 153, 158–64
- weight gain, 45, 110, 118, 203, 212
- weight loss, 228, 234, 235, 246
- widespread pain index, 286